<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798664</url>
  </required_header>
  <id_info>
    <org_study_id>PCS-2018C1-11326</org_study_id>
    <nct_id>NCT04798664</nct_id>
  </id_info>
  <brief_title>Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening</brief_title>
  <official_title>Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of four interventions to promote sustained, biochemically&#xD;
      confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer&#xD;
      screening at four large U.S. health systems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained,&#xD;
      biochemically confirmed smoking abstinence for 6 months among smokers in underserved&#xD;
      demographic groups. The 3,200 participants to be enrolled will be current smokers who are&#xD;
      Black, Hispanic, and/or have low socioeconomic status (defined as household income &lt;200% of&#xD;
      the federal poverty line or a high school education or less) or rural residence who are&#xD;
      referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All&#xD;
      adult patients with LDCT orders will be further screened for eligibility. Eligible patients&#xD;
      will enroll and complete the study using the NIH-funded Way to Health online research portal.&#xD;
      The primary outcome will be biochemically confirmed, sustained abstinence from smoking&#xD;
      tobacco for 6 months following participants' selected quit dates. Relapse rates will be&#xD;
      tracked at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective randomized controlled trial with longitudinal follow-up of patients over 12 months. Based on the expected accrual at each of the four health systems, we expect that overall there will be 470 participants in basic usual care (Arm 1), and 910 participants in each of intervention arms 2-4.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemically confirmed smoking abstinence sustained for 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quit status (self-report)</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Point-prevalent rates of self-reported nicotine use and tobacco product use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quit status (biochemically confirmed)</measure>
    <time_frame>2 weeks, 3 months, 6 months,12 months</time_frame>
    <description>Point-prevalent rates of biochemically confirmed smoking cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The EuroQuol Group's quality of life (EQ-5D) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived barriers to cessation</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting) and extrinsic factors (social or environmental aspects of quitting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy related to cessation efforts</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation to quit</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal (&quot;delay&quot;) discounting</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Basic Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives plus Mobile Health Application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the &quot;future is now&quot; between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Removal of Financial Barriers</intervention_name>
    <description>Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications</description>
    <arm_group_label>Enhanced Usual Care</arm_group_label>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives</arm_group_label>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives plus Mobile Health Application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Financial Incentives</intervention_name>
    <description>Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.</description>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives</arm_group_label>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives plus Mobile Health Application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mobile Health Application</intervention_name>
    <description>Episodic future thinking tool to overcome temporal discounting of future</description>
    <arm_group_label>Enhanced Usual Care plus Financial Incentives plus Mobile Health Application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current smoker (â‰¥ 1 cigarettes per day, not including e-cigarettes)&#xD;
&#xD;
          -  Has a low-dose computed tomography (LDCT) scan ordered by their physician&#xD;
&#xD;
          -  Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c)&#xD;
             rural residence, or (d) low socioeconomic status (Defined as one or both of:&#xD;
             high-school education or less, or household income &lt;200% of the federal poverty line)&#xD;
&#xD;
          -  Able to receive study invitation and screening, by virtue of showing up to a radiology&#xD;
             location affiliated with a participating health system for the LDCT, or having a valid&#xD;
             email address or telephone number on file with the health system&#xD;
&#xD;
          -  Access to a cell phone with text messaging or the internet&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No cell phone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott D Halpern, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothy Sheu, MS</last_name>
    <phone>215-746-3433</phone>
    <email>Dorothy.Sheu@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Madden</last_name>
    <email>vmadden@upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaiser Permanente Southern California</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Gould, MD MS</last_name>
    </contact>
    <investigator>
      <last_name>Michael Gould, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Ismail, MD MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Neslund-Dudas, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christine Neslund-Dudas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Simoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Facktor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Facktor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Collins, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott D Halpern, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Halpern, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anil Vachani, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Hart, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Volpp, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Kohn, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dylan Small, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alisa Stephens-Shields, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients, Underserved</keyword>
  <keyword>Early Detection of Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Nicotine Replacement Products</keyword>
  <keyword>Incentives</keyword>
  <keyword>Behavioral Economics</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie published results will be made available to other researchers, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months after publication and up to 36 months following publication. After 36 months the data will be available in our University's data warehouse but without support, except for deposited metadata.</ipd_time_frame>
    <ipd_access_criteria>Proposals for data use will be reviewed by Principal Investigator and independent review board (such as the Data and Safety Monitoring Board). Approved requestors will need to sign data use agreements to access and use data.</ipd_access_criteria>
    <ipd_url>https://www.pair.upenn.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

